ROLLOVER AND SUPPORT AGREEMENTRollover and Support Agreement • October 19th, 2023 • Vivo Capital IX, LLC • Services-medical laboratories • New York
This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 11, 2023 by and between New Genetron Holding Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”) and the persons set forth on Schedule A hereto (each, a “Rollover Shareholder”, and collectively, “Rollover Shareholders”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
JOINT FILING AGREEMENTJoint Filing Agreement • February 3rd, 2020 • Vivo Capital IX, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, no par value, of Trillium Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.
JOINT FILING AGREEMENTJoint Filing Agreement • October 19th, 2023 • Vivo Capital IX, LLC • Services-medical laboratories
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Ordinary shares, par value $0.00002 of Genetron Holdings Limited, is being filed and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • December 30th, 2019 • Vivo Capital IX, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value, of Selecta Biosciences, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.
